Physician profile
Stanley M Marks
NPI 1477524924
$41,115.90
in general payments reported to CMS, 2019-2025
17 companies · $593 in 2025
The $593 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $7,928 · 2021: $6,965 · 2022: $54.64 · 2023: $1,719 · 2024: $924 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866 · Consulting Fee: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.86 |
| Consulting Fee | $1,370.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21,465.26 | 2019-2025 | Calquence |
| Verastem, INC. | $6,061.87 | 2019 | |
| Exelixis INC. | $5,974.60 | 2019-2024 | Cabometyx |
| Dendreon Pharmaceuticals LLC | $3,385.22 | 2019 | |
| Karyopharm Therapeutics INC. | $2,475.00 | 2021 | |
| Stemline Therapeutics INC. | $555.08 | 2023-2025 | Orserdu |
| Beone Medicines USA, INC. | $262.00 | 2025 | Brukinsa |
| Beigene USA, INC. | $236.13 | 2023-2024 | Brukinsa |
| Celgene Corporation | $143.47 | 2019 | |
| Genmab U.S., INC. | $134.68 | 2024 | |
| Janssen Biotech, INC. | $105.85 | 2019 | |
| Seagen INC. | $101.12 | 2023 | Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $99.99 | 2019 | |
| Lilly USA, LLC | $52.58 | 2024-2025 | Jaypirca, Verzenio |
| Acrotech Biopharma INC. | $37.87 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $25.18 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$910,622.51 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.